Company news
Enliven Therapeutics, Inc. (NASDAQ:ELVN) news
Enliven Therapeutics, Inc. news releases on 6ix. Latest, Dec 14, 2021: Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH)…
Press releases — page 2
Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021
December 13, 2021
Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
December 12, 2021
Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease
November 21, 2021
Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia
November 15, 2021
Imara Reports Third Quarter 2021 Financial Results and Business Highlights
November 8, 2021
Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)
November 7, 2021
Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights
November 3, 2021
Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021
November 3, 2021
Imara to Participate in Upcoming Investor Conferences
September 14, 2021
Imara to Present at Upcoming Investor Conferences
September 2, 2021
Imara Reports Second Quarter 2021 Financial Results and Business Highlights
August 5, 2021
Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease
August 4, 2021
Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights
July 29, 2021
Imara Announces Pricing of Public Offering
July 12, 2021
Imara Announces Launch of Proposed Public Offering
July 12, 2021
Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors
June 29, 2021
Imara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders
June 16, 2021
Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
June 10, 2021
Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
June 3, 2021
Imara Reports First Quarter 2021 Financial Results and Business Highlights
May 10, 2021
Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights
May 3, 2021
Imara Opens Applications for the Second-Annual ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders
March 28, 2021
Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and Beta-Thalassemia
March 16, 2021
Imara Reports Full Year 2020 Financial Results and Business Highlights
March 4, 2021
Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights
February 25, 2021
Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference
February 18, 2021
Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer
January 19, 2021
Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease
January 5, 2021
Imara Presents IMR-687 Phase 2a Open Label Extension Case Reports on Two Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition
December 6, 2020
Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition
November 29, 2020
Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory
November 16, 2020
Imara Reports Third Quarter 2020 Financial Results and Business Highlights
November 4, 2020
Imara to Webcast Conference Call of Third Quarter Financial Results
October 28, 2020
Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia
October 15, 2020
Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease
August 24, 2020
Imara Reports Second Quarter 2020 Financial Results and Business Highlights
August 13, 2020
Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease
August 12, 2020
Imara to Webcast Conference Call of Second Quarter 2020 Financial Results
August 6, 2020
Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia
July 29, 2020
Imara Added to Membership of U.S. Small-Cap Russell 2000® Index
June 28, 2020
Imara Receives Orphan Drug Designation for IMR-687 for Treatment of Beta-thalassemia
June 23, 2020
Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress
June 11, 2020
Imara to Present Data on IMR-687 in Sickle Cell Disease at the 25th Annual European Hematology Association (EHA) Congress
May 20, 2020
Imara Reports First Quarter 2020 Financial Results and Business Highlights
May 6, 2020
Imara Launches ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders
May 5, 2020
Imara Announces Appointment of Stephen M. Migausky as General Counsel
May 3, 2020
Imara Strengthens Board of Directors With Appointment of Edward R. Conner, M.D.
April 22, 2020
IMARA Announces Pricing of Initial Public Offering
March 10, 2020